BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
Trade with 70% Backtested Accuracy
Analyst Views on BCTXL
No data
About the author
BRIACELL THERAPEUTICS CORP TO ALLOCATE UP TO $3 MILLION FOR BRIAPRO RESEARCH AND DEVELOPMENT
Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.
Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.
BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
BRIACELL AND BRIAPRO SIGN ASSET PURCHASE AGREEMENT FOR EXCLUSIVE LICENSE OF SOLUBLE CD80
Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.
Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BRIACELL THERAPEUTICS CORP TO ALLOCATE UP TO $3 MILLION FOR BRIAPRO RESEARCH AND DEVELOPMENT
Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.
Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.
BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
BRIACELL AND BRIAPRO SIGN ASSET PURCHASE AGREEMENT FOR EXCLUSIVE LICENSE OF SOLUBLE CD80
Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.
Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
